Mylan Cautiously Optimistic About India Market Following Approval Of Agila Acquisition
This article was originally published in PharmAsia News
The global generics giant hopes to take a quantum leap in its business prospects. But Mylan remains cautious about striking business deals in India in the wake of changing pricing and policy dynamics.
You may also be interested in...
With release of draft bioequivalence guidance for GSK’s blockbuster asthma and COPD treatment, generics seem more likely than ever, but there may be only a select number of companies who can meet the guidance’s requirements.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.